We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Everest Medicines announced the first patient has been dosed in China into the EVER-132-001 Phase 2b registration clinical trial evaluating Trodelvy (sacituzumab govitecan, IMMU-132) for the treatment of patients with metastatic triple-negative ...